" This transaction brings significant external financial investment to Nicox's commercial operations in Europe, supporting the future growth of the business and allowing Nicox to focus on its global therapeutic R&D pipeline. Importantly, it enables us to remain involved in and benefit from the future value of the European and International commercial business that we have worked hard to develop over the last 3 years, without any further direct financial investment by Nicox in the commercial activities, " commented Michele Garufi, Chairman and CEO of Nicox, adding, " We see this agreement as a true collaboration, bringing together GHO Capital's long-standing investment expertise and Nicox's commercial and therapeutic knowledge in the ophthalmology space. Nicox will remain involved in the new organisation as an equity stakeholder and as a business partner.